

Index

Page numbers in **bold** represent tables, those in *italics* represent figures.

- absolute erythrocytosis, 440
 ABT. *See* allogeneic blood transfusion
 accreditation, for blood transfusion, 174
 acquired haemostatic defects, 269–74
 disseminated intravascular coagulation, 269–71
 liver disease, 271, 272
 massive transfusion, 271
 trauma, 271
 uraemia, 272
 activated clotting time (ACT), 412
 activated factor VII (FVIIa), 263
 activated partial thromboplastin time (APTT), 264, 326, 393, 413
 activated recombinant factor VII (rFVIIa), 512
 AcuStar[®] system, 330
 acute haemolytic transfusion reaction (AHTR), 80–84
 ABO-incompatibility and, 80–82
 from ABO-incompatible platelet transfusions, 87
 aetiology and incidence of, 80–82
 complications of, 82
 fatal, **81**
 immediate medical management of, 82, **83**
 intravascular haemolysis in, 77
 investigation of suspected, 82, 83
 management of confirmed, 84
 prevention of, 84
 SHOT voluntary reporting scheme on, 81, 82
 signs and symptoms of, 82
 acute lung injury (ALI), 98
 acute lymphoblastic leukaemia (ALL), 457
 acute myeloid leukaemia (AML), 457, 476
 acute normovolaemic haemodilution (ANH), 287, 288, 392, 405
 disadvantages of, 289
 acute respiratory distress syndrome (ARDS), 98
 acylated plasminogen-streptokinase activator complex (APSAC), 273
 ADAMTS13, 437
 adaptive immune cells, 11, 12
 ADCC. *See* antibody-dependent cell-mediated cytotoxicity (ADCC)
 additional manual systems
 of patient identification, 233
 adrenal vein thrombosis, 326
 adverse transfusion reactions
 bacterial contamination and, 144, 145
 AFSSAPS. *See* Agence Française de Sécurité Sanitaire des Produits de Santé
 Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS), 172, 175
 AHTR. *See* acute haemolytic transfusion reaction
 AIHA. *See* autoimmune haemolytic anaemia
 allergic transfusion reactions, 92–5
 antipyretics for, 94
 clinical presentation of, 92
 differential diagnosis of, 92, 93
 IgA deficiency associated with, 95
 incidence of, 93
 management of, 93, 94
 pathogenesis of, 93
 prevention of, 94, 95
 Alliance of Blood Operators (ABO), 178
 grouping
 by donor red cells testing, 202
 in pretransfusion compatibility testing, 244, **244**
 incompatibility, 447, 448. *See also* haemopoietic progenitor cell (HPC)
 incompatible bone marrow, 311, **311**, 312
 incompatible platelet transfusions
 causes AHTR, 87
 incompatible transplants
 in DHTR, 86
 Alliance Pharmaceutical Company, 405
 allogeneic blood transfusion (ABT), 106
 non-leucocyte-reduced, 109–11
 randomized controlled trial of, *111*
 randomized controlled trial of, *110*
 short-term mortality and, 109–11
 allogeneic mononuclear cells (AMC), 106
 TRIM effects mediated by, 107, 108
 allogeneic plasma
 TRIM effects and, 109
 α-methyl dopa, 303
 AMC. *See* allogeneic mononuclear cells (AMC)
 American Association of Tissue Banks (AATB), 480
 American Society for Apheresis (ASFA), 438
 American Society of Hematology, 509
 America's Blood Centers (ABC), 178
 7-Aminoactinomycin, 447
 amotosalen, 214–17
 anaemia
 acute, 284
 and acute haemorrhage, 284, 285
 cold-type autoimmune haemolytic, 245
 and death, relationship between, 494.
 See also transfusion medicine
 warm-type autoimmune haemolytic, 245
 anaphylactic and anaphylactoid reactions, 92
Anaplasma phagocytophilum, 140
 angiotensin-converting enzyme (ACE) inhibitor, 93
 ANH. *See* acute normovolaemic haemodilution
 anti-A,B antibodies, 78, 79
 antibody-dependent cell-mediated cytotoxicity (ADCC), 78
 antibody screening
 in pretransfusion compatibility testing, 244, 245
 antifibrinolytics, 289, 290, 410–12
 mechanism of action of, 412
 antigen presenting cells (APC), 440
 antihistamines, in allergic transfusion reactions, 94
 anti-Jk^a antibodies, in HTR, 79
 anti-Lu^a antibodies, in HTR, 79
 antipyretics, in allergic transfusion reactions, 94
 apheresis, 433
 blood components collection by, 209–10
 blood donors for, 199
 complications of therapeutic, 440, 441
 therapeutic, 433
 Apixaban, 273
 aplastic anaemia patients, 122
 aprotinin, 290, 392, 411, 412
 antikallikrein effect of, 412

INDEX

- APSAC. *See* acylated plasminogen-streptokinase activator complex
 APTT. *See* activated partial thromboplastin time
 ARDS. *See* acute respiratory distress syndrome
 arterial blood gas analysis, 278
 arthropod-borne viruses, 139
 artificial platelet substitutes, 407
 ASFA. *See* American Society for Apheresis Asia
 improving clinical use of blood in, 258
 ASPEN syndrome, 439
 Audit, 516, 517
 auscultation, of lungs, 98
 Australian Commission on Safety and Quality in Healthcare, 231
 autoantibodies
 pretransfusion compatibility testing, 245
 autoimmune haemolytic anaemia (AIHA), 300
 autologous transfusion, 390–97, 391, 395
 acute normovolaemic haemodilution, 289, 392
 blood conservation
 effective methods for, 392, 393
 strategies, 391
 cell salvage, 394–7
 labelling, 395
 mechanical cell salvage, 289
 pre-deposit donation, 391
 preoperative autologous donation, 285, 289
 reasons to consider, 390, 391
 transfusion targets, 394, 394
 transfusion triggers, 393, 394
 Babesiosis, 140, 141
Babesia, 134, 163
 BacT/ALERT System, 148
 bacterial contamination, 144–50
 blood components susceptible to, 144, 145
 plasma and cryoprecipitate, 145
 platelet concentrates, 144, 145, 148
 red blood cells, 145
 contaminant species, 145, 146
 incidence of, 144
 investigation of transfusion reactions, 146, 147
 prevalence of, 148
 prevention strategies for, 146, 147–50
 bacterial detection, 148, 149
 donor screening, 147
 pathogen reduction technologies, 149, 150
 skin disinfection, 147
 single donor apheresis *vs.* pooled platelet Concentrates, 144
 sources of, 146, 146
 bar codes, for patient identification, 528
 Bayesian analysis, 499. *See also* transfusion medicine
 BeadChip™, 529
 Beriplex®, 272
 Bernard Soulier syndrome, 414
 Bethesda inhibitor assay, 268
 biological response modifiers (BRM)
 in FNHTR, 90
 Biologics License Application (BLA), 171
 blood and marrow transplants,
 classification of indications for, 458
 Blood and Safety Quality Regulations (BSQR), 210
 BLOODchip™, 528
 blood collection/donation, 198, 199
 altruistic, 190
 directed and payback, 191
 RCC and plasma production from, 210
 screening tests on, 207
 blood components
 administration of, 233–7, 236
 collection and delivery of, 236
 collection by apheresis, 209, 210
 cryoprecipitate and cryosupernatant, 220, 221
 fresh frozen plasma, 217–20
 definition, 217
 pathogen inactivation, 217–20, 219
 specification for, 217, 218
 vCJD and, 220
 for intrauterine transfusion, 221, 222
 leucocyte-reduced, 210–14
 pathogen inactivation in red cells, 213
 prion reduction in red cells, 213, 214
 production of, 210, 11
 red cell components, 211, 213
 specifications for, 211, 211
 viruses and prions removal by, 211
 platelet concentrates, 214–17
 pathogen reduction in, 214–17
 production of, 214, 216
 storage, 214
 prescription of, 234
 processing of blood to, 209, 210
 production from whole blood, 209
 quality monitoring, 210
 requests for, 235
 susceptible to bacterial contamination, 144, 145
 plasma and cryoprecipitate, 145
 platelet concentrates, 144, 145, 148
 red blood cells, 145
 transfused granulocytes, 221
 blood conservation strategies, 391. *See also* autologous transfusion
 blood donation testing
 microbiological testing, 204–7
 donor management in, 204
 donor–recipient matching, 206, 207
 infectious disease testing, 205, 206
 repeat-reactive sample principles, 204, 205
 sample collection, 204
 screening tests, 206, 207, 207
 testing process, 204
 operational and quality control issues in, 207, 208
 overview, 201
 red cell serological testing, 201–4
 ABO grouping, 202
 antiglobulin testing, 203
 detecting irregular blood group antibodies, 202, 203
 phenotyped red blood cells, 203, 204
 RhD grouping, 202
 sample collection, 201, 202
 blood donor, 190, 191
 adverse events or reactions in, 193
 altruistic, 190, 194
 for apheresis, 199
 blood collection process, 198, 199
 deferral criteria for, 196–8
 European Union (EU) Directive for, 195
 infections risks from, 195
 iron deficiency in, 191–4
 management in Europe, 191
 motivates to, 190
 obligations to, 199, 200
 paying, 190, 191
 recruiting voluntary, in sub-Saharan Africa, 253
 risks to, 191–4
 selecting of, 191, 194
 source of bacterial contaminants, 146
 transfusion-transmissible agents in sub-Saharan African, 257
 blood establishments, 231
 blood group antigens, 29
 blood group systems, 20–29, 22
 ABO system, 21–23
 A and B subgroups, 23
 biosynthesis and molecular genetics, 23, 24
 clinical significance, 21–3
 Diego, 22, 28
 Duffy, 22, 26–8, 28
 H, 22, 24
 I, 22, 24
 Kell, 22, 26
 Kidd, 22, 28
 Lewis, 22, 24
 MNS, 22, 28
 Rhesus, 23, 24
 bloodless surgery, 394
 blood quality
 regulatory authorities role in, 172
 blood safety, 250–52
 in sub-Saharan Africa, 254, 255
 WHO objectives to ensure, 251
 Blood Safety and Quality Regulations, 231
 blood services
 deferral rates in, 194
 blood stem cells, 86, 424, 455, 456

INDEX

- blood substitutes, 399–408, 400
 perfluorocarbons, 404, 405
 first-generation fluorocarbons, 405
 Oxygent, 405
 platelet substitutes, 405–7
 platelet membrane preparations, 406
 synthetic platelets, 406, 407
 red cell substitutes, 400, 401
 encapsulated haemoglobins, 403
 haemoglobin-based, 400, 401
 intramolecularly crosslinked
 haemoglobin, 401–3
 second-generation haemoglobin-based,
 403, 404
 virtual, 399, 400
 blood supply, 250–52
 cost of local, 254
 global, overview, 250
 regulatory authorities role in, 172, 173
 in sub-Saharan Africa, 253–5
 blood transfusion
 agencies role, 179
 errors and problems in, 234
 haemorrhage and, 230
 regulation for
 donor involvement in, 179
 national, 172
 patient involvement, 178, 179
 professional organizations role in, 178
 regulation, functional components of,
 173–5
 application and enforcement of
 regulations, 174
 cost effectiveness, 174, 175
 guiding principles and law, 173, 174
 standards, 174
 regulatory bodies/authorities, 175–9
 involved in regulatory processes,
 176–8
 national statutory bodies, 175
 role of, 172–3
 supranational agencies, 175–8
 services
 centralization of, 241, 242
 importance of, 171
 public accountability of, 171
 regulation *vs.* medicine regulation,
 171, 172
 in sub-Saharan Africa, 252, 253
 systems
 in sub-Saharan Africa, 252
 blood-transmitted infections
 improving screening for, 256–8
 in sub-Saharan Africa, 256
 B lymphocytes, 13
 Antigens, 46
 BMT. *See* bone marrow transplantation
 BNP. *See* B-type natriuretic peptide
 bone marrow, 445. *See also* haemopoietic
 progenitor cell (HPC)
 bone marrow failure, 304. *See also* platelet
 transfusions
 bone marrow transplantation (BMT), 455
Borrelia burgdorferi, 140
 bovine haemoglobin, 403
 BRM. *See* biological response modifiers
 (BRM)
 BSQR. *See* Blood and Safety Quality
 Regulations (BSQR)
 B-type natriuretic peptide (BNP)
 in TRALI, 101
Burkholderia cepacia, 146
 B19V. *See* human B19 parvovirus
 Cancer Immunotherapy Consortium, 531
 CAP. *See* College of American Pathologists
 (CAP)
 cardiopulmonary bypass, 273. *See also*
 coagulation disorders
 surgery, 305
 CARS. *See* compensatory
 anti-inflammatory response
 syndrome (CARS)
 CD34+ enrichment, 448. *See also*
 haemopoietic progenitor cell (HPC)
 CD34 enumeration, 446, 447. *See also*
 haemopoietic progenitor cell (HPC)
 CD40 ligand
 in FNHTR, 90
 cell salvage, 394–7. *See also* autologous
 transfusion
 intraoperative cell salvage, 395, 396
 principle, 394
 relative contraindications, 396, 397
 cell separators, 433, 434
 cellular immunotherapy. *See*
 immunotherapy
 cellular therapy. *See also* transfusion
 medicine
 cancer treatment, immunotherapy in,
 531, 532
 economics of, 532, 533
ex vivo generation of blood components,
 532
 haematopoietic stem cell
 transplantation, 531
 in nonmalignant diseases, 532
 CENTRAL. *See* Cochrane Central Register
 of Controlled Trials
 centralized transfusion service (CTS), 241,
 242
 CER. *See* comparative effectiveness
 research
 Chagas disease, 141
 chimeric antigen receptor (CAR), 475, 476.
See also immunotherapy
 ciclosporin, in red cell transfusion, 302
 Clauss fibrinogen, 264
 clinical practice, 237–41
 audit, 238, 239, 239
 education and continuing professional
 development, 241
 EQA schemes, 240
 fear of litigation, 240
 guidelines, algorithms and protocols,
 237, 238
 investigation of serious adverse events,
 240, 241
 national schemes, 239, 240
 ‘near miss’ and, 240
 public and political perceptions, 240
 surveys, 239
 Clinical Randomization of an
 Antifibrinolytic in Significant
 Haemorrhage, 2 (CRASH-2), 410
 CliniMacs™ instrument, 448
Clostridium perfringens, 145, 149
 CMV antibody testing
 for blood donation, 206, 207
 coagulation disorders, 263–74
 abnormal haemostasis, 264, 264–6
 acquired, 269–74
 disseminated intravascular
 coagulation, 269–71
 liver disease, 271, 272
 massive transfusion, 271
 prothrombotic conditions, 273, 274
 trauma, 271
 uraemia, 272
 anticoagulant and thrombolytic drugs,
 272, 273
 inherited, 266–9
 haemophilia A, 266, 267
 haemophilia B, 267, 268
 von Willebrand disease, 268, 269
 normal haemostasis, 263, 264
 coagulation, physiological response of,
 277. *See also* massive blood loss
 coagulopathy, 290
 defined, 290
 diagnosis, 290, 291
 treatment, 291–7
 FFP transfusion, 292
 fibrinogen replacement, 292–5
 platelet transfusion, 291, 292
 prothrombin complex concentrates,
 295–7
 Cobe 2991 cell processor, 451
 COBE Spectra, 437
 Cochrane Central Register of Controlled
 Trials (CENTRAL), 508, 510
 Cochrane Collaboration Effective Practice
 and Organization of Care, 516
 cold haemagglutinin, chronic, 302
 cold-type autoimmune haemolytic anaemia,
 245
 College of American Pathologists (CAP),
 174
 colony-forming units (CFU), 443, 447
 column-agglutination systems, 243, 243
 comparative effectiveness research (CER),
 510
 compensatory anti-inflammatory response
 syndrome (CARS), 109–11
 complement components (C1–C9)
 in HTR, 79

INDEX

- confidence interval (CI), 289, 412, 494, 507
- confounding, defined, 494. *See also* transfusion medicine
- conjugated haemoglobin, 403. *See also* blood substitutes
- cord blood transplantation, 464–71
- adults, 467, 468
 - advantages, 469, 469, 470
 - in children, 466
 - related, 466, 467
 - unrelated, 466, 467
 - clinical results, 466–9
 - malignant disease, 466, 467, 467, 468
 - metabolic disorders, 467
 - primary immunodeficiencies, 467–9
 - cord blood banking, 465, 465, 466, 466
 - disadvantages, 469, 469, 470
 - future developments, 470, 470
 - reducing risk of infection, 465
- coumarin, 272
- Coxiella burnetii*, 140
- Creutzfeldt–Jakob disease, variant, 134, 141, 152–8, 163
- aetiology and pathophysiology, 153, 154
 - cell, tissue and organ transplantation, 159
 - clinical transmission, 155
 - component processing, 158
 - donor screening, 156, 157
 - donor selection, 155, 156
 - fresh frozen plasma, 217
 - imported blood products, 156
 - optimal use of blood components, 159
 - peripheral blood infectivity, 155
 - plasma products, 158, 159risk containment, 155
- cryoprecipitate, 220, 221, 269, 279, 292
- selection of, 248
- cryosupernatant, 220, 221
- ¹⁴Cserotoninrelease assay (SRA), 327
- CSL Behring, 272
- CTS. *See* centralized transfusion service (CTS)
- Cutaneous T-cell lymphoma (CTCL), 440
- Cytomegalovirus*, 138
- cytomegalovirus (CMV), 460
- infection, transfusion-transmitted, 306, 306, 307
 - clinical features and risk factors, 306
 - prevention, 306, 307
 - removal by leucocyte reduction, 211
- cytotoxic T-cell therapy, 461. *See also* haemopoietic stem cell transplantation (HSCT)
- cytotoxic T-lymphocytes (CTL), 474
- dabigatran, 273, 331, 530
- damage control surgery, 278. *See also* massive blood loss
- DAT. *See* direct antiglobulin test
- data management
 - in haemovigilance system, 186
- data standardization
 - in haemovigilance system, 182, 183
- DDAVP. *See* 1-deamino-8-D-arginine vasopressin
- 1-deamino-8-D-arginine vasopressin (DDAVP), 399
- decay accelerating factor, 18
- deep-vein thrombosis (DVT), 326
- DEHP. *See* Diethyl hexyl phthalate
- delayed haemolytic transfusion reaction (DHTR), 84–7
- aetiology and incidence of, 84, 85
 - extravascular haemolysis in, 77
 - haemopoietic stem cell transplantation in, 86
 - investigation of suspected, 85
 - management of, 85
 - passenger lymphocyte syndrome and, 86
 - prevention of, 86, 87
 - sickle cell disease and, 86, 87
 - symptoms and signs of, 85
- delayed serological transfusion reaction (DSTR), 85
- Deltaretrovirus*, 138
- Desmopressin, 287, 288, 290, 412
- desmopressin acetate (DDAVP), 412
- dextrans, 278
- DHTR. *See* delayed haemolytic transfusion reaction (DHTR)
- diaspirin crosslinked haemoglobin, 401. *See also* blood substitutes
- DIC. *See* disseminated intravascular coagulation
- Diego blood group system, 22, 28
- diethyl hexyl phthalate (DEHP), 526
- dimethyl sulfoxide (DMSO), 437, 450, 451
- 2,3-diphosphoglycerate (2,3-DPG), 279, 400
- direct antiglobulin test (DAT), 203, 301
- disseminated intravascular coagulation (DIC), 82, 269–71, 292, 325
- causes of, 270
 - and haematological disease, 305
- DLI. *See* donor lymphocyte infusion
- DNA sequencing, 36–7, 37
- DOMAINE Donor Management in Europe Project, 191
- Donath–Landsteiner test
 - for paroxysmal cold haemoglobinuria, 302, 303, 303
- donor blood storage
 - in sub-Saharan Africa, 253
- donor lymphocyte infusion (DLI), 443, 445, 461, 473
- donor lymphocytes, 446. *See also* haemopoietic progenitor cell (HPC)
- Donor Management Manual*, 191
- donor–recipient matching
 - microbiological testing and, 206, 207
- donor screening
 - antibody assays for, 206
 - in bacterial contamination, 147
 - decision on, 171
 - 2,3-DPG. *See* 2,3-diphosphoglycerate
 - DQA* gene, 33
 - DQB* gene, 33
 - DRA* gene, 33
 - DRB* gene, 33
- DSTR. *See* delayed serological transfusion reaction (DSTR)
- Duffy blood group system, 22, 26, 27
- Duffy glycoprotein, 29
- DVT. *See* deep-vein thrombosis
- Dysfibrinogenaemia, 269, 271
- EACA. *See* epsilon amino caproic acid
- EBM. *See* evidence-based medicine
- EBMT. *See* European Group for Blood and Marrow Transplantation
- EBV. *See* Epstein–Barr virus (EBV)
- Eculizumab, 529, 530
- electronic bedside systems
 - for safe blood transfusion, 233–7
- electronic crossmatch, 247
- embryonic stem cells (ESC), 531
- EMA. *See* European Medicine Evaluation Agency
- enzyme immunoassay (EIA)
 - WHO evaluation of, 257
- enzyme-linked immunosorbent assay (ELISA), 325
- epsilon amino caproic acid (EACA), 289, 410, 412
- Epstein–Barr virus (EBV), 138, 461, 531
- EQA schemes. *See* external quality assessment (EQA) schemes
- error reduction
 - of pretransfusion compatibility testing, 244
- erythropoietin, 272, 285
- Escherichia coli*, 145, 149, 401
- ethylenediamine tetra-acetic acid (EDTA), 247
- Eubacterium limosum*, 149
- European Blood Alliance (EBA), 178
- European Group for Blood and Marrow Transplantation (EBMT), 311
- European Haemovigilance Network (EHN), 192
- European Medicine Evaluation Agency (EMA), 436
- European Project and Haemorrhage Reduction (EUPHRATES), 276
- European Union (EU), 462
- European Union Tissue and Cells Directives (EUTCD), 480, 486
- evidence-based medicine (EBM), 505
- exchange transfusion
 - to treat hyperbilirubinaemia in neonates, 222

INDEX

- external quality assessment (EQA) schemes
clinical practice and, 240
- extracorporeal photochemotherapy (ECP),
440
- extravascular haemolysis, 77
causes of, 79
- factor XI deficiency, 269
- family-replacement donors (FRD), 251
- FDP. *See* fibrin degradation products
- febrile nonhaemolytic transfusion reactions
(FNHTR), 89–92
antibody mechanism causes, 90
clinical presentation of, 89
differential diagnosis of, 89, 90
frequency of, 90
management of, 91
pathogenesis of, 90
patient susceptibility in, 90, 91
premedication in, 92
prevention of, 91, 92
- Feedback, 516, 517
- FEIBA[®], 268
- FFP. *See* fresh frozen plasma (FFP)
- fibrin degradation products (FDP), 269
- fibrinogen, 279
replacement, 292–5, 293, 294. *See also*
coagulopathy
- fibrinolysis, 263
- Flavivirus*, 138
- fluorocarbon
first-generation, 405
- fluosol, 405
- Fluosol-DA 20*, 405
- FNHTR. *See* febrile nonhaemolytic
transfusion reactions (FNHTR)
- Fore-Sight[®], 529
- FRD. *See* family-replacement donors
(FRD)
- fresh frozen plasma (FFP), 217–20, 279,
293, 437
definition, 217
effects of, 295
in intrauterine transfusion, 222
methylene blue, 220
pathogen inactivation, 217–20, 219
solvent–detergent, 220
specification for, 217, 218
transfusion, 292
vCJD and, 220
- frozen plasma (FP), 519
- F-*tert*-butylcyclohexane, 405
- G-CSF. *See* granulocyte colony-stimulating
factor (G-CSF)
- Ghana, blood transfusion systems in, 252
- Glanzmann thrombasthenia, 413, 414
- globin chains, 400
- glutaraldehyde crosslinked haemoglobin,
402–3. *See also* blood substitutes
- glycoprotein (GP), 414
- GMP. *See* good manufacturing practice
- good blood management, 284
in acute haemorrhage, 284
- good manufacturing practice (GMP), 173,
440, 478, 524
- Goodpasture's syndrome, 438
- GRADE (Grading of Recommendations
Assessment, Development and
Evaluation), 509
- graft-*versus*-leukaemia (GVL), 444, 455,
466, 473
- graft-*versus*-malignancy (GVM), 466
- granulocyte
transfusion, 118, 221, 305, 306. *See also*
haematological disease
- granulocyte colony-stimulating factor
(G-CSF), 221, 305, 434, 464
- granulocyte-macrophage colony
stimulating factor (GM-CSF), 434
- group sequential methods, 499
- Guillain–Barré syndrome, 438
- GVHD. *See* graft-*versus*-host disease
(GVHD)
- haematological disease, 300–12
alloimmunization to red cell antigens,
310, 311
background, 300
granulocyte transfusions, 305, 306
HLA alloimmunization, 308–10
iron overload, 311, 312
massive blood transfusion, 304, 305
platelet transfusions, 304, 305
bone marrow failure, 304
cardiopulmonary bypass surgery,
305
disseminated intravascular
coagulation, 305
immune thrombocytopenias, 304
massive blood transfusion, 304, 305
refractoriness to, 308–10, 309, 309
red cell transfusion, 300–303
chronic anaemias, 301
immune blood disorders, 301–3
patients receiving
myelosuppressive/myeloablative
treatment, 300, 301
recombinant erythropoietin, 301
transfusion-transmitted agents
cytomegalovirus, 306, 306, 307
graft-*versus*-host disease, 307
- haematopoietic stem cell transplantation
(HSCT), 531
- Haemocue, 394
- haemoglobin (Hb), 391
conjugated, 403
diaspirin crosslinked, 401
encapsulated, 403
glutaraldehyde crosslinked, 402, 403
intramolecularly crosslinked, 401–3
conjugated haemoglobin, 403
diaspirin crosslinked haemoglobin,
401
- glutaraldehyde crosslinked
haemoglobin, 402, 403
- O-raffinose crosslinked haemoglobin,
403
- polymerized haemoglobin, 402
- recombinant haemoglobin, 401, 402
- O-raffinose crosslinked, 403
- polymerized, 402
- recombinant, 401, 402
- haemolysis, 303
- haemolytic disease of the fetus and
newborn (HDFN), 222, 245
- haemolytic transfusion reaction (HTR),
77–88
ABO incompatibility and, 79
Acute, 80–84
aetiology and incidence of, 80–82
complications of, 82
fatal, 81
immediate medical management of,
82, 83
investigation of suspected, 82, 83
management of confirmed, 84
prevention of, 84
signs and symptoms of, 82
antibody specificities associated with, 80,
80
anti-Jk^a antibodies in, 79
anti-Lu^a antibodies in, 79
defined, 77
delayed, 84–7
aetiology and incidence of, 84, 85
investigation of suspected, 85
management of, 85
passenger lymphocyte syndrome and,
86
prevention of, 86, 87
sickle cell disease and, 86, 87
symptoms and signs of, 85
pathophysiology of, 77–80, 78
activation of complement antibodies,
79
antibody and antigen characteristics,
78, 79
antigen–antibody interactions and, 77
Fc receptor interactions, 79
generation of cytokines, 79, 80
in sickle cell disease, 86, 87
wrong blood incidents and, 81, 84
- haemophilia A, 266, 267
clinical manifestations and treatment of,
266
- haemophilia B, 267, 268
clinical manifestations and treatment of,
266
- Haemophilus influenzae B* (HIB), 460
- haemopoietic progenitor cell (HPC), 433,
443–52, 474, 476
- ABO incompatibility, 447, 448
assays, *in vitro*, 447
background, 443
CD34+ enrichment, 448

INDEX

- haemopoietic progenitor cell (HPC)
(*Continued*)
CD34 enumeration, 446
collection, 436–7
cryopreservation, 449–52
ex vivo expansion, 448
human, 444
mobilization, 434–6, 435
products, 445, 446
assessment, 446–9
bone marrow, 445
donor lymphocytes, 446
peripheral blood, 445, 446
storage of, 449, 450
umbilical cord blood, 446
quality assurance, 452
sterility testing, 447
T-cell depletion, 448, 449
thawing of cryopreserved, 452
transplant procedures, 443–5
allogeneic SCT, 444, 445
autologous SCT, 443, 444
donor lymphocyte infusions, 445
viability assays, 447
- haemopoietic stem cells (HSC), 531
- haemopoietic stem cell transplantation (HSCT), 455–62
chimerism and molecular monitoring, 461
complications, 458–60
early post-engraftment period, 460
graft-*versus*-host disease, 459
immediate post-transplant phase, 459, 460
infectious complications, 459, 460
late problems, 460
regimen-related toxicity, 458, 459
rejection, 459
relapse, 459
- cytotoxic T-cell therapy, 461
in DHTR, 86
donors, 456
HLA matching, 456
immunotherapy, 461
indications for, 456–8
outcome
acute leukaemia, 461
chronic myeloid leukaemia, 460, 461
principles of, 455, 456
reduced intensity conditioning, 455
regulatory aspects, 462
sources of stem cells, 456
- haemorrhage
acute, good blood management in, 284
blood transfusion and, 230
obstetric, 276, 411
protocols, 297
uncontrolled, 276
- haemostasis, 263, 264, 277
abnormal, 264, 264–6
- haemovigilance, 174
in TA-GVHD, 124
- haemovigilance module, 527
- haemovigilance system
encouragement of active participation in, 185, 186
IHN definition of, 181
important features of, 182
key elements of, 182–7
adverse events, detection of, 183, 184
breadth of system, 186, 187
data management, 186
data standardization, 182, 183
definitions and terminology, 182, 183
limitations of, 184
'near-miss' events, 184
organizational structure in Europe, 182
origin of, 181, 182
principles of, 187
reporting in
of adverse events, 183, 184
analysis of incident reports, 184, 185
compliance of, 185
errors, 184, 185
scope of, 184
selecting professionals for, 183
tying with bedside system, 183
reviewing past transfusion data, 187, 188
role in blood transfusion, 181
TRALI risk and, 187, 188
transfusion safety in, 187, 188
and transfusion system, 184
variations among, 184
- HAS. *See* human albumin solution
- HAV. *See* hepatitis A virus
- Hawthorne effect, 518
- HbS testing, for blood donation, 203, 204
- HBV. *See* hepatitis B virus
- HCV. *See* hepatitis C virus
- health professionals, role of, 179
- HemosIL AcuStar HIT-IgG_(PF4-H), 330, 331
- HemosIL HIT-Ab_(PF4-H), 330
- HemoStase, 413
- HEP. *See* HIT expert probability
- Hepacivirus*, 136
- Hepadnavirus*, 135
- heparin-induced platelet activation (HIPA), 327
- heparin-induced thrombocytopenia (HIT), 322, 333
anaphylactoid reactions, 327
anticoagulant in, 332
clinopathologic syndrome, 324–7, 325
epidemiology of, 323, 324
iceberg model, 325, 326
isolated, 331
laboratory testing of, 327–31
PF4-dependent immunoassays, 329, 329–31
platelet activation assays, 327–9
pathogenesis of, 322, 323, 324
transfusion medicine, 323
treatment of, 331–3
- hepatitis A virus (HAV), 135
- hepatitis B virus (HBV), 135, 136
- hepatitis C virus (HCV), 136
- hepatitis E virus (HEV), 137
- herpesvirus, 138, 211, 460
- hereditary clotting factor deficiencies, 413, 414. *See also* recombinant activated factor VII (rFVIIa)
- HEV. *See* hepatitis E virus (HEV)
- high titre anti-A, 202, 203
- high titre anti-B, 202, 203
- high-titre haemolysins
screening of plasma containing, 203
- HIPA. *See* heparin-induced platelet activation
- HIT. *See* heparin-induced thrombocytopenia
- HIT expert probability (HEP), 327
- HIV Combo assay
blood donation and, 205, 206
- HLA *see* human leukocyte antigen
- Hodgkin lymphoma, 307, 443
- homozygous HLA donors, 123
- hospital setting, for transfusion, 230–49
blood and blood components
administration of, 233–7, 236
collection and delivery of, 236
prescription of, 234
requests for, 235
clinical practice, 237–41
audit, 238, 239, 239
education and continuing professional development, 241
EQA schemes, 240
fear of litigation, 240
guidelines, algorithms and protocols, 237, 238
investigation of serious adverse events, 240, 241
national schemes, 239, 240
'near miss' and, 240
public and political perceptions, 240
surveys, 239
electronic bedside systems, 233–7
errors and outcomes, 234
maximum surgical blood ordering schedule, 247, 248, 248
overview, 230, 231
pretransfusion compatibility testing, 242–8
ABO grouping, 244, 244
antibody identification, 245
antibody screening, 244, 245
autoantibodies, 245
electronic issues, 247
plasma components selection, 248
platelets selection, 248
red cell antigen-antibody detection, 242, 243
red cell crossmatching, 246, 247
red cell selection, 245, 246
reduction of error in, 244

INDEX

- RhD grouping, 244
 sampling for, 235
 reduction of misidentification errors, 233–7
 barcoded systems, 233–7
 manual systems, 233
 transfusion governance, key features, 231
- hospital transfusion committees (HTC), 231–3
 activities of, 232
 membership to, 233
 organizational structure of, 232, 233
- hospital transfusion governance
 EQA schemes and, 231
 key features of, 231
- HPA. *See* human platelet antigen
- HSCT. *See* haematopoietic stem cell transplantation
- HTC. *See* hospital transfusion committees
- HTLV-1. *See* human T-lymphotropic viruses 1
- HTLV-2. *See* human T-lymphotropic viruses 2
- HTR. *See* haemolytic transfusion reaction
- human albumin solution (HAS), 437
- human B19 parvovirus (B19V), 139
- human herpesviruses, 138
- human immunodeficiency virus (HIV), 137
- human leucocyte antigens (HLA), 12, 31–43, 279, 305, 444
 alloimmunization to, 308–10, 309, 310
 antibodies
 clinical relevance, 40
 detection, 38, 39
 formation, 38
 class I, 31
 class II, 33
 genetic organisation and expression, 32, 33
 clinical relevance, 38, 40
 and disease, 41
 hereditary haemochromatosis, 42
 neonatal alloimmune thrombocytopenia, 42, 43
 expression, 34
 function, 34, 35
 gene polymorphism, 35, 36
 DNA sequencing-based typing, 37
 PCR-sequence-specific oligonucleotide probing, 36, 37
 PCR-sequence-specific priming, 36
 genetics, 34
 human platelet antigen (HPA), 304
- Human Tissue Act, 480
- Human Tissue Authority (HTA), 456, 462, 480
- human T-lymphotropic viruses 1 (HTLV-1), 138
- human T-lymphotropic viruses 2 (HTLV-2), 138
- hydroxyethyl starch (HES), 278, 448
- hyperbilirubinaemia
 exchange transfusion to treat, 222
- hyperhaemolytic transfusion reactions, 86, 87
 in sickle cell disease, 86, 87
- hyperkalaemia, 281
- hypothermia, prevention of, 278. *See also* massive blood loss
- hypovolaemic shock, 285
- hypoxia, 98
- IAT. *See* indirect antiglobulin test (IAT)
- IBCT. *See* incorrect blood component transfusion (IBCT)
- IBMTR. *See* International Bone Marrow Transplant Registry
- ICS. *See* intraoperative cell salvage
- IgA deficiency, 95
- IgG antibodies
 causes extravascular haemolysis, 79
- IgG-mediated haemolysis, 79
- IHN. *See* International Haemovigilance Network (IHN)
- immune blood disorders and red cell transfusion, 301–3, 302. *See also* red cell transfusion
 cold antibody AIHA, 302, 302
 drug-induced AIHA, 302, 303
 paroxysmal cold haemoglobinuria, 302, 302, 303
 warm antibody AIHA, 301, 302, 302
- immune thrombocytopenias, 304. *See also* platelet transfusions
- immunoassay
 infectious disease testing, 205, 206
- immunoglobulin-like transcript (ILT), 476
- immunotherapy, 473–9
 chimeric antigen receptor, 475, 476
 cytokines in, 476
 and GVHD, 473
 haemopoietic stem cell transplantation, 473
 nonspecific T-cell immunotherapy, 473, 474
 passive therapy of infectious diseases, 477, 478
 T-cell receptor gene transfer, 474, 475, 475
 translational research, 478, 479
 tumour-restricted natural killer cells, 476, 476, 477
 tumour-specific/restricted T-cell immunotherapy, 474–6
- INAHTA. *See* International Network of Agencies of Health Technology Assessment
- incorrect blood component transfusion (IBCT), 81
- indirect antiglobulin test (IAT), 203, 242
- induced pluripotent stem cells (iPSC), 404, 531
- infectious disease testing, 205, 206
 immunoassay, 205, 206
 nucleic acid testing, 206
- inferior vena cava filters, 332
- inherited haemostatic defects, 266–9
 haemophilia A, 266, 267
 haemophilia B, 267, 268
 von Willebrand disease, 268, 269
- INR. *See* international normalized ratio
- inspection
 during blood transfusion, 174
- In-spectra[®], 529
- intensive care unit (ICU), 284
- INTERCEPT process, 150
- International Bone Marrow Transplant Registry (IBMTR), 460, 473
- International Haemovigilance Network (IHN), 181
- International Network of Agencies of Health Technology Assessment (INAHTA), 508
- international normalized ratio (INR), 326
- International Plasma Fractionation Association (IPFA), 178
- International Plasma Producers Congress (IPPC), 178
- International Society for Blood Transfusion (ISBT), 443
- International Society for Cytotherapy (ISC), 456
- International Society for Thrombosis and Haemostasis (ISTH), 270, 270
- International Society of Blood Transfusion (ISBT), 178, 183
- International Study of Infarct Survival, 496
- intraoperative cell salvage (ICS), 392, 395
 advantages of, 396
 disadvantages of, 396
 indications for, 396
- intrauterine transfusion (IUT)
 blood components for, 221, 222
 of neonates, 222
 platelet concentrates and FFP in, 222
 requirements, 221, 222
 UK specifications for red cells for, 221
- intravascular haemolysis, 77
 causes of antibody-mediated, 79
- intravenous immunoglobulin (IVIg), 332, 438
- investigational medicinal products (IMP), 478
- ionizing radiation
 in TA-GVHD, 118
- IPFA. *See* International Plasma Fractionation Association (IPFA)
- IPPC. *See* International Plasma Producers Congress (IPPC)
- iPSC. *See* induced pluripotent stem cells
- iron deficiency, in blood donors, 191–4
- iron overload, 311, 312. *See also* haematological disease

INDEX

- irradiated products
for TA-GVHD, 123
- irregular blood group antibodies
red cell serological testing, 202, 203
- ISBT. *See* International Society for Blood Transfusion
- ISTH. *See* International Society for Thrombosis and Haemostasis
- Ivory Coast
blood transfusion systems in, 252
- JACIE, 227–9
- JCAHO. *See* Joint Commission on Accreditation of Healthcare Organizations
- Jehovah's Witnesses, 301, 396
- Joint Accreditation Committee of EBMT, 456
- Joint Commission on Accreditation of Healthcare Organizations (JCAHO), 231
- Kallikrein inhibitory units (KIU), 411
- Kell antigen, 310
- Kidd and Duffy antibodies, 85
- Kidd (Jk) antibodies, 80
- killer immunoglobulin-like receptor (KIR), 476, 477
- Klebsiella oxytoca*, 149
- Klebsiella pneumoniae*, 145
- lactate dehydrogenase (LDH), 439
- Lentivirus*, 137
- lethal triad, 271
- leucocytapheresis, 436, 437
- leucocyte-derived soluble mediators
TRIM effects and, 108, 109
- leucocyte filters, 392
- leucocyte inactivation
in TA-GVHD, 117
- leucocyte-reduced blood components, 210–14
pathogen inactivation in red cells, 213
prion reduction in red cells, 213, 214
production of, 210, 211
red cell components, 211–13
specifications for, 211, 211
viruses and prions removal by, 211
- leucocyte-reduced platelet components
volume and platelet content for, 215
- leucocyte-reduced red cell components
volume and haemoglobin content for, 212
- leucocyte reduction
adverse TRIM effects and, 107
in allergic transfusion reactions, 94
in TA-GVHD, 118
- leukaemia-free survival (LFS), 461
- LFS. *See* leukaemia-free survival
- licensing
for blood transfusion, 174
- liposome, 406
- liquid-phase systems, 242, 243
- litigation, fear of, 240
- liver disease, 271, 272. *See also* acquired haemostatic defects
- LMWH. *See* low-molecular-weight heparin
- long-term culture initiating cells (LTC-IC), 447
- low-molecular-weight heparin (LMWH), 322
- Luminex™, 529
- lymphoproliferative disorder (LPD), 461
- lysine analogues
perioperative use of, 411, 411
- MAC. *See* membrane attack complex (MAC)
- major histocompatibility complex (MHC), 406, 445
- malaria, 140
- market surveillance
blood transfusion and, 174
- massive blood loss, 276–81
bleeding, management of, 277, 277, 278
blood component use, 278, 279
coagulation
factor concentrates, 279, 280
physiological response of, 277
definition of, 276
fluid management, 278
future, 281
haematological management, 280, 281
hypothermia, prevention of, 278
management of, 280
- massive blood transfusion, 297, 304, 305
- maximum amplitude (MA), 265
- maximum surgical blood ordering schedule (MSBOS), 247, 248, 248
- MCID. *See* minimal clinically important difference
- mechanical cell salvage, 287, 288, 289. *See also* autologous transfusion
- Medicines and Healthcare Products Regulatory Agency (MHRA), 84, 175, 207
- medicolegal aspects, 224–9
consent to transfusion, 226, 227
duty of care, 226
ethical principles, 224
Jehovah's Witnesses, 227, 228
patient recourse, 228, 229
quality guidelines, 226
UK regulatory framework, 224–6
Consumer Protection Act 1987, 224, 225
European Blood Safety Directives (2002/98), 225, 226
Medicines Act 1968, 224
NHS Act 1999 and Health and Social Care Act 2006, 225
see also regulatory aspects
- membrane attack complex (MAC), 78
- mesenchymal stem cells (MSC), 531
- 8-methoxypsoralen (8-MOP), 440
- methylcellulose (MC), 447
- methylene blue fresh frozen plasma (MBFFP), 220
- methylene blue (MB), 217
- MHC. *See* major histocompatibility complex
- MHRA. *See* Medicines and Healthcare Products Regulatory Agency (MHRA)
- microbiological testing, 204–7. *See also* red cell serological testing
donor management in, 204
donor–recipient matching, 206, 207
infectious disease testing principles, 205, 206
immunoassay, 205, 206
nucleic acid testing, 206
repeat-reactive sample principles, 204, 205
sample collection, 204
screening tests, 206, 207, 207
testing process, 204
- Microchimerism (MC), 124
transfusion-associated, 124, 125
- microspheres, fibrinogen-coated, 406
- Miltenyi Biotec, 448
- minimal clinically important difference (MCID), 501
- minimally important difference (MID), 501
- Mirasol® system, 150
- Mistransfusion, 230
- MODS. *See* multiple-organ dysfunction syndrome (MODS)
- mononuclear cells (MNC), 440
- MOOSE (meta analysis of observational studies in epidemiology), 508
- Morganella morganii*, 149
- MSBOS. *See* maximum surgical blood ordering schedule (MSBOS)
- multiple-organ dysfunction syndrome (MODS), 109–11
- multiple organ failure (MOF), 106
- myasthenia gravis, 438
- myelodysplastic syndrome, 311
- National Blood Policy, 172
- National Healthcare Safety Network, 527
- National Health Service Blood and Transplant (NHSBT), 201
- National Health Service (NHS), 517
- National Institute for Health and Clinical Excellence (NICE), 397
- National Patient Safety Agency, 231, 297
- natural cytotoxicity receptor (NCR), 476
- 'near-miss' events, 184, 240
- Natural killer (NK) cells, 11
- neonatal alloimmune neutropenia, 58, 59, 362

INDEX

- neonatal alloimmune thrombocytopenia, 19, 42, 43, 45, 127, 222, 349, 355, 359
- antenatal management, 54, 55
- clinical features, 52, 53
- counselling, 55
- definition, 52
- differential diagnosis, 53
- history, 52
- HPA-typed donor panels, 55, 56
- incidence, 52
- laboratory investigations, 53
- neonatal management, 54
- pathophysiology, 52
- post-transfusion purpura, 127, 128
- pregnancies at risk for, 355
- neonates
- intrauterine transfusion for, 222
- top-up transfusions for, 222
- NHSBT. *See* National Health Service Blood and Transplant (NHSBT)
- NICE. *See* National Institute for Health and Clinical Excellence
- Nigeria
- national transfusion service in, 254
- non-leucocyte-reduced ABT, 109–11
- randomized controlled trial of, 111
- nonmalignant diseases, cellular therapy in, 532. *See also* transfusion medicine
- nucleic acid testing (NAT)
- for blood donation, 206
- obstetric haemorrhage, 276, 411
- octapharma, 272
- Octaplex[®], 272
- optical density (OD), 329
- O-raffinose crosslinked haemoglobin, 403.
- See also* blood substitutes
- Oxycyte, 405
- Oxygent, 405
- PAD. *See* preoperative autologous donation
- PaGIA. *See* particle gel immunoassay
- PAHO. *See* Pan American Health Organization (PAHO)
- Pan American Health Organization (PAHO), 178
- Paraproteinaemia, 439
- parasitic diseases, 140, 141
- babesiosis, 140, 141
- Chagas disease, 141
- detection and management, 134
- malaria, 140
- paroxysmal cold haemoglobinuria, 302, 303. *See also* haematological disease
- Donath–Landsteiner test for, 303
- participation, in haemovigilance, 185, 186
- particle gel immunoassay (PaGIA), 330
- particle immunofiltration assay (PIFA), 330
- passenger lymphocyte syndrome, 86
- pathogen inactivation
- in fresh frozen plasma, 217–20, 219
- in red cells, 213
- pathogen reduction, in platelets, 214–17
- using riboflavin, 217
- pathogen reduction technology (PRT), 149, 150, 526
- patient identification
- additional manual systems of, 233
- Paul Erlich Institute (PEI), 172, 175
- PBSC. *See* peripheral blood stem cells
- PCC. *See* prothrombin complex concentrate
- PCS. *See* postoperative cell salvage
- PEI. *See* Paul Erlich Institute
- perfluorocarbon (PFC), 404, 405
- first-generation fluorocarbons, 405
- Oxygent, 405
- principle, 404, 405
- third-generation, 405
- perfluoro-octylbromide (PFOB), 405
- perfortan, 405
- peripheral blood (PB), 434
- peripheral blood progenitor cell
- transplants, 311, 311
- peripheral blood stem cells (PBSC), 455
- PFC. *See* perfluorocarbons
- PF4-dependent immunoassays, 329, 329–31. *See also* heparin-induced thrombocytopenia (HIT)
- PFOB. *See* perfluoro-octylbromide
- Phenindione, 272
- phenotyped red blood cells testing, 203, 204
- HbS testing, 203, 204
- testing in selected group, 203
- phlegmasia cerulea dolens, 326
- photopheresis, 440
- PIFA. *See* particle immunofiltration assay
- PLADO. *See* Platelet Dose
- plasma components
- selection in pretransfusion compatibility testing, 248
- plasma exchange, 433, 437–9, 438
- kinetics of, 438
- Plasma Protein Therapeutics Association (PPTA), 178
- plasma reduction
- in allergic transfusion reactions, 94, 95
- Plasmodium*, 140
- platelet activation assays, 327–9. *See also* heparin-induced thrombocytopenia (HIT)
- washed, 327–9
- platelet concentrates/components, 214–17
- in intrauterine transfusion, 222
- pathogen reduction in, 214–17
- production of, 214, 216
- storage, 214
- susceptible to bacterial contamination, 144, 145
- platelet consumption, 309
- platelet defects, inherited, 414. *See also* recombinant activated factor VII (rFVIIa)
- Platelet Dose (PLADO), 497
- platelet factor 4 (PF4), 322
- platelet membrane preparations, 406
- platelet refractoriness, 308
- causes of, 308, 309, 309
- management of, 309, 310
- platelet-rich plasma (PRP), 214
- platelets, 279. *See also* massive blood loss
- platelet substitutes, 405–7
- platelet membrane preparations, 406
- synthetic platelets, 406, 407
- platelet transfusion, 291, 292, 292, 304, 305. *See also* coagulopathy; haematological disease
- bone marrow failure, 304
- cardiopulmonary bypass surgery, 305
- disseminated intravascular coagulation, 305
- immune thrombocytopenias, 304
- massive blood transfusion, 304, 305
- prophylactic, 304
- refractoriness to, 308–10, 309, 309
- Plerixafor (Mozobil), 435
- polyethylene glycol (PEG), 435
- polymerase chain reaction (PCR), 460, 492
- polyvinyl sulfonate (PVS), 322
- postoperative cell salvage (PCS), 392, 397
- posttransfusion purpura (PTP)
- haemovigilance data on, 188
- posttransplant lymphoproliferative disorders (PTLD), 531
- PPTA. *See* Plasma Protein Therapeutics Association
- prekallikrein, 269
- preoperative autologous donation (PAD), 285, 287, 288, 289
- pretransfusion compatibility testing, 242–8
- ABO grouping, 244, 244
- antibody identification, 245
- antibody screening, 244, 245
- autoantibodies, 245
- electronic issues, 247
- plasma components selection, 248
- platelets selection, 248
- red cell
- antigen-antibody detection, 242, 243
- crossmatching, 246, 247
- selection, 245, 246
- reduction of error in, 244
- RhD grouping, 244
- sampling for, 235
- primary immunodeficiency syndromes, 467–9. *See also* cord blood transplantation
- prions
- causes transfusion-transmitted infections, 141
- detection and management, 134

INDEX

- prions (*Continued*)
 reduction in red cells, 213, 214
 removal by leucocyte reduction, 211
- PRISMA (preferred reporting items for systematic reviews and meta-analyses), 508
- procoagulant pathway, 264
- prophylactic platelet transfusions, 304
- Propionibacterium acnes*, 145, 149
- protamine sulfate, 393
- Proteus morgani*, 149
- prothrombin complex concentrate (PCC), 267, 269, 272, 279, 295–7, 331, 530
- prothrombin time (PT), 264, 413
- Provenge[®], 533
- PRP. *See* platelet-rich plasma (PRP)
- PRT. *See* pathogen reduction technology
- Pseudomonas aeruginosa*, 146
- Pseudomonas cepacia*, 146
- Pseudomonas fluorescens*, 146
- PTLD. *See* posttransplant lymphoproliferative disorders
- PTP. *See* posttransfusion purpura
- pulmonary dysfunction, 97
- pulmonary transfusion reactions
 clinical information for diagnosis of, 102
- purpura, post-transfusion, 127–30
 clinical features, 127, 128
 definition, 127
 differential diagnosis, 128
 incidence, 127
 laboratory investigations, 128
 management, 129
 pathophysiology, 128, 129
 prevention of recurrence, 129, 130
- QALY. *See* quality-adjusted life year (QALY)
- quality-adjusted life year (QALY), 175
- quality management system
 in blood donation testing, 207, 208
- randomized controlled trial (RCT), 410, 491, 495–502, 502, 505
 challenges in, 506
 design alternatives, 497, 497–500, 498
 design for, 495–7, 496
 outcomes, 501, 501, 502
 composite, 502
 surrogate, 502
 study population, 500, 500, 501
- Raph blood group system, 22
- Raynaud's disease, 302
- RCC. *See* red cell concentrates
- recombinant activated factor VII (rFVIIa), 290, 413–15
 hereditary clotting factor deficiencies, 413, 414
 off-licence use, 414
 pharmacological doses of, 413
- randomized controlled trial evidence, 414, 415, 415
 safety considerations, 415
- recombinant erythropoietin (RhEpo)
 in haematological disease, 301
- recombinant FVIIa, 271
- recombinant haemoglobin, 401, 402. *See also* blood substitutes
- recombinant human erythropoietin (RhEpo), 287, 288, 289
- recombinant proteins, 368–74
 antibodies, 369–72
 anti-HPA-1a, 372, 373
 anti-prion, 372
 human, 370, 371
 human monoclonal anti-D, 371, 372
 'null', 373
 phenotyping reagents, 373
- antigens, 373–4
 blood groups, 373
 microbial, 373
- coagulation factors, 374
- enzymes, 374
- expression, 368, 369
- red blood cells (RBC)
 adverse effects of transfusion of old, 112, 113
 adverse TRIM effects and components, 106, 107
 artificial, 403
 contaminant bacterial species, 145, 146
 susceptible to bacterial contamination, 145
- red cell alloantibodies
 selection of blood for patients with, 246
- red cell antigen-antibody detection, 242, 243
 column-agglutination systems, 243, 243
 liquid-phase systems, 242, 243
 solid-phase systems, 243, 243
- red cell antigens, alloimmunization to, 310, 311. *See also* haematological disease
- red cell components, 211–13
- red cell concentrates (RCC)
 production from blood donation, 210
- red cell crossmatching, 246, 247
- red cell exchange, 439, 440
 advantage of, 439
- red cell serological testing, 201–4. *See also* microbiological testing
 ABO grouping, 202
 antiglobulin testing, 203
 detecting irregular blood group antibodies, 202, 203
 high titre anti-A and anti-B, 202, 203
 phenotyped red blood cells, 203, 204
 testing for HbS, 203, 204
 testing in selected group, 203
- RhD grouping, 202
- sample collection, 201, 202
- red cell substitutes, 400, 401, 402. *See also* blood substitutes
 encapsulated haemoglobins, 403
 haemoglobin-based, 400, 401
 intramolecularly crosslinked haemoglobin, 401–3
 modified haemoglobin-based blood substitutes, 400, 401, 401
- red cell transfusion, 284, 285, 300–303.
See also haematological disease
 anaemia and acute haemorrhage, 284, 285
 chronic anaemias, 301
 immune blood disorders, 301, 303
 indications for, 285, 286
 patients receiving
 myelosuppressive/myeloablative treatment, 300, 301
 recombinant erythropoietin, 301
 in trauma, 279
- reduced intensity conditioning (RIC), 455, 458, 459
- Regulatory T cells (T regs), 13
- relative light units (RLU), 331
- repeat-reactive sampling
 in blood donation, 204, 205
- rFVIIa. *See* recombinant activated Factor VII; recombinant activated factor VII
- RhD grouping
 pretransfusion compatibility testing, 244
 by testing donor red cells, 202
- RhD red cells transfusion, 245, 246
- RhEpo. *See* Recombinant human erythropoietin
- RhEpo, in premature infants, 222
- risk reduction
 of transfusion-transmitted infections, 230, 231
- rituximab, 274, 529
 in red cell transfusion, 302
- Rivaroxaban, 273
- ROTEM[®], 290, 291, 529
- ROTEMR[®], 265
- SaBTO. *See* Safety of Blood, Tissues and Organs (SaBTO)
- SAFE. *See* Saline-versus-albumin fluid evaluation
- Safe Blood for Africa Foundation, 252
- Safety of Blood, Tissues and Organs (SaBTO), 211
- saline-versus-albumin fluid evaluation (SAFE), 496
- Sanguis Study Group, 519
- SCID. *See* severe combined immune deficiency syndrome
- sc-Fv phage libraries, 371
- Scianna blood group system, 22
- Serious Hazard of Transfusion (SHOT), 182, 244, 396
 confidential reporting scheme, 81, 82

INDEX

- ¹⁴Cserotoninrelease assay, 327
Serratia marcescens, 146, 148, 149
 severe combined immune deficiency syndrome (SCID), 469
 shock index, 277
 short tandem repeats (STR), 461
 SHOT. *See* serious hazard of transfusion
 sialic acid, 403
 sickle cell disease, 397, 434
 sickle cell haemolytic transfusion reaction (SCHTR) syndrome, 87
 Sipuleucel-T, 532
 SIRS. *See* systemic inflammatory response syndrome (SIRS)
 skin disinfection
 in bacterial contamination, 147
 solid-phase systems, 243, 243
 solvent–detergent fresh frozen plasma, 220
 Spectra Optia, 437
 splenectomy, 302
 SRA. *See* ¹⁴Cserotoninrelease assay
Staphylococcus aureus, 145, 149
Staphylococcus epidermidis, 145
Staphylococcus saccharolyticus, 149
 stem cell
 allogeneic, 456
 autologous, 456
 collection
 patient assessment and treatment planning, 434–7
 comparison of sources of, 457
 damage, 435
 syngeneic cells, 456
 sterility testing, 447. *See also* haemopoietic progenitor cell (HPC)
 streptokinase, 273
 streptomycin, 505
 STROBE, 507
 stromal-derived factor 1 (SDF-1), 434
 sub-Saharan Africa
 blood transfusion systems in, 252
 clinical use of blood in, 254
 improving, 258
 epidemiology of bloodborne infections in, 256
 organization of transfusion services in, 252, 253
 recruiting voluntary donors in, 253
 reducing cost of transfusion in, 258
 screening for blood-transmitted infections, 256–8
 testing and storage of donor blood, 253
 WHO objectives for blood supply in, 254
 WHO ‘volunteer only’ policy effects in, 251, 252
 supranational agencies
 with statutory powers, 175
 with treaty-defined powers and remits, 178
 synthetic platelets, 406, 407
 systemic inflammatory response syndrome (SIRS), 109–11
 systemic lupus erythematosus nephritis (SLE), 439
 TACO. *See* transfusion-associated circulatory overload
 TAD. *See* transfusion-associated dyspnoea
 TAGVHD. *See* transfusion-associated graft-versus-host disease
 TA-MC. *See* transfusion-associated microchimerism
 TAP1, 35
 TAP2, 35
 T cells, 11
 Antigens, 46
 Depletion, 448, 449
 TEG[®], 265, 529
 abnormalities in, 265
 TFPI. *See* tissue factor pathway inhibitor
 T helper (Th) cells, 12, 13
 therapeutic apheresis, 433
 Therapeutic Cells-Apheresis, 445
 Therapeutic Cells-T Cells, 445
 threat surveillance
 of infectious disease, 174
 thrombin, 263, 264
 thrombin time (TT), 271
 thrombocytopenia, 265, 291, 304, 325
 Thromboelastogram (TEG[®]), 290
 thromboelastography, 265
 thromboembolctomy, 331
 thromboembolic disease, 414
 thrombotic thrombocytopenic purpura (TTP), 273, 274, 438
 tissue banking, 480–86
 clinical applications, 484, 484
 consent, 480, 481
 deceased donors, 480
 donor testing, 482
 tissue procurement, 482, 483
 donor selection and testing, 481, 482
 living donors, 480
 donor testing, 482
 tissue procurement, 482, 483
 regulation of, 480
 serious adverse events/reactions, 484, 485
 supply and traceability of tissues, 483, 484
 tissue processing, 483
 processing facilities, 483
 and regenerative medicine, 485, 486
 tissue procurement, 482, 483
 tissue factor pathway inhibitor (TFPI), 263
 tissue factor (TF), 263
 tissue plasminogen activator (tPA), 405
 T-lymphocytes, 11, 307, 444
 topical sealants, 412, 413
 top-up transfusions
 for neonates, 221, 222
 total body irradiation (TBI), 459
 tPA. *See* tissue plasminogen activator
 TRALI. *See* transfusion-related acute lung injury
 tranexamic acid (TA), 266, 269, 289, 410, 411
 in traumatic bleeding, 410, 411
 transfused granulocytes, 221
 transfused patient
 management of, 233–7
 monitoring of, 237
 transfusion-associated circulatory overload (TACO), 101, 290
 and haemovigilance systems, 188
 transfusion-associated dyspnoea (TAD), 101, 290
 transfusion-associated graft-versus-host disease (TA-GVHD), 116–24, 307
 blood component factors in, 118, 120
 cases reported to SHOT, 121
 clinical features, 116, 117
 defined, 116
 diagnosis of, 117
 haemovigilance in, 124
 irradiated products for, 123
 irradiation in
 adverse effects of, 118, 119
 guidelines, 119
 universal, 123, 124
 pathogenesis and clinical features, 307
 pathogenesis of, 116
 patients at risk for, 120–23
 aplastic anaemia patients, 122
 cardiovascular surgery patients, 122, 123
 congenital immunodeficiency patients, 120
 fetuses and neonates, 122
 HIV/AIDS patients, 122
 HPC transplant recipients, 120
 immunocompetent patients, 123
 leukaemia and lymphoma patients, 120–22
 patients receiving chemotherapy and immunotherapy, 122
 recipients of fludarabine, 122
 solid organ transplantation recipients, 122
 prevention, 117, 118, 307, 308
 leucocyte inactivation, 117
 source and dose of ionizing radiation, 118
 treatments of, 117
 transfusion-associated microchimerism (TA-MC), 124, 125
 clearance of lymphocytes in, 124
 clinical data of, 124
 consequences of, 125
 testing for, 124, 125
 limitations of, 125
 transfusion medicine
 case-control study, 492
 evidence for, 505–14

INDEX

- transfusion medicine (*Continued*)
- alternatives to transfusion, 512, 513
 - CER, 510
 - clinical evidence, hierarchies of, 505, 506
 - frozen plasma, 511
 - limitations in, 512, 514
 - narrative and systematic reviews, 507–9, 509, 510
 - platelets, 511, 512
 - primary research evidence, 506, 506, 507
 - systematic reviews and guidelines, 509, 510
- future changes, 524–34, 534
- blood collection and component production, 524–7
 - cellular therapy, 531–3
 - diagnostics, 528, 529
 - donor collections, 524–6
 - health and healthcare, priorities of, 533, 534
 - hospital blood transfusion practice, 527–30
 - national blood donors, 529
 - horizon scanning, 525
 - observational and interventional trials in
 - difficulties in, 491, 492
 - observational studies, 492–5, 493
 - randomized controlled trials, 495–502
 - types of studies, 492
- transfusion reactions
- anaphylactic, 66
 - delayed serological, 85
 - reactions hypotensive, 69
 - transfusion-related alloimmune neutropenia, 58, 59
- transfusion requirements in critical care (TRICC) study, 7
- transfusion practice
- aim of, 230
 - guidelines for, 258
 - variation in, 516–22
 - background, 516
 - behaviour/change models, 519–21, 520
 - comparing interventions, 517–19, 518
 - implementation research, 521
 - interventions to change practice, 516, 517
- transfusion-related acute lung injury (TRALI), 97–104, 290, 493
- blood components causes, 99
 - chest X-rays of patient with, 98
 - clinical manifestation of, 98, 99
 - defined, 97
 - differential diagnosis of, 101, 102, 102
 - and haemovigilance systems, 187, 188
 - incidence of, 97
 - lung histology and, 100, 101
 - mitigation strategies in, 103
 - outcome and morbidity in, 103
- pathogenesis of, 99, 100
 - patient management, 102, 103
 - and TACO, 101
 - thin section of fixed lung of patient with, 100
- transfusion-related immunomodulation (TRIM), 106
- effects, 107
 - allogeneic plasma and, 109
 - clinical studies of adverse, 106, 107
 - mediated by AMC, 107, 108
 - mediated by leucocyte-derived soluble mediators, 108, 109
 - mediated by soluble molecules, 109
 - RBC components in, 106, 107
 - postulated mediators of, 107
 - transfusion requirements in critical care (TRICC), 279, 497, 519
 - transfusion safety officers (TSO), 183
 - transfusion system, 184
 - transfusion-transmissible agents
 - prevalence in sub-Saharan African donors, 257
- transfusion-transmitted infection (TTI), 132–42, 290
- agents of, 135–41
 - bacteria, 139, 140
 - parasites, 140, 141
 - prions, 141
 - viruses, 135–39
 - by blood transfusion, 132, 133
 - detection and management of, 133, 134
 - interventions for, 134, 135
 - overview, 132
 - risk reduction of, 230, 231
- trauma, 271. *See also* acquired haemostatic defects
- Massive Transfusion Protocol in, 296
 - red cell transfusion in, 279
- Treg cells, 440
- Treponema pallidum*, 140
- TRICC. *See* transfusion requirements in critical care
- TRIM. *See* transfusion-related immunomodulation
- trypan blue (TB), 447
- Trypanosoma cruzi*, 141
- TSO. *See* transfusion safety officers
- 4Ts pretest probability score, 328
- TTI. *See* transfusion-transmitted infection
- TTP. *See* thrombotic thrombocytopenic purpura
- tumour-associated antigens (TAA), 474
- tumour-specific antigens (TSA), 474
- tyrosine kinase inhibitors (TKI), 461
- UFH. *See* unfractionated heparin
- UK Cell Salvage Action Group (UKCSAG) guidelines, 396
- UK regulatory framework, 224–6
- Consumer Protection Act 1987, 224, 225
 - European Blood Safety Directives (2002/98), 225, 226
 - Medicines Act 1968, 224
 - NHS Act 1999 and Health and Social Care Act 2006, 225
- umbilical cord blood transplant (UCBT), 464–71. *See also* cord blood transplantation
- umbilical cord blood (UCB), 446, 464. *See also* haemopoietic progenitor cell (HPC)
- unfractionated heparin (UFH), 322
- United States Agency for International Development (USAID), 252
- universal irradiation
 - in TA-GVHD, 123, 124
- universal leucocyte reduction, 495
- uraemia, 272. *See also* acquired haemostatic defects
- USAID. *See* United States Agency for International Development
- US Food and Drug Administration (FDA), 405, 436, 530
- variant Creutzfeldt–Jakob disease (vCJD), 141, 210, 493
- fresh frozen plasma and, 220
- varicella zoster infection, 271
- vCJD. *See* variant Creutzfeldt–Jakob disease
- virus
- causes transfusion-transmitted infections, 135–9
 - arthropod-borne viruses, 139
 - cytomegalovirus, 138
 - detection and management, 133, 134
 - hepatitis A virus, 135
 - hepatitis B virus, 135, 136
 - hepatitis C virus, 136
 - hepatitis E virus, 137
 - HIV, 137
 - human B19 parvovirus, 139
 - human herpesviruses, 138
 - human T-lymphotropic viruses, 138
 - West Nile virus, 138, 139
 - inactivation
 - of cryoprecipitate and cryosupernatant, 220, 221
 - removal of cell-associated, 211
 - vitamin K antagonists, 272, 272, 273. *See also* coagulation disorders
 - vitamin K deficiency, 273. *See also* coagulation disorders
 - VNRD. *See* volunteer nonremunerated donors (VNRD)
 - volunteer nonremunerated donors (VNRD), 251
 - von Willebrand disease (vWD), 268, 269, 414
 - functions of, 268
 - types of, 268
 - variants of, 268

INDEX

von Willebrand factor (vWF), 290, 412
VWD. *See* von Willebrand disease
VWF. *See* von Willebrand factor

warfarin, 331
warm-type autoimmune haemolytic
anaemia, 245

Weibel–Palade bodies, 290, 412
West Nile virus (WNV), 138, 139
WNV. *See* West Nile virus (WNV)
World Health Organization (WHO)
objectives for blood safety and supply,
251, 252
'wrong blood' events, 230

wrong blood in tube (WBIT) events, 240,
241

Yersinia enterocolitica, 145

Zimbabwe
blood transfusion systems in, 252

